KAZIA THERAPEUTICS LTD
KZIANasdaq
$13.34
↑ +1.7%Jul 17 close · end-of-day
Price
1Y↑ +30.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Kazia Therapeutics Limited is an oncology-focused biotechnology company. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway. It is also developing EVT801, an investigational new drug for various forms of cancer.
- CEO
- James S. Garner
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 12
- Website
- kaziatherapeutics.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jun 2, 2026
Apr 28, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.